Several financial analysts have recently reviewed their ratings and price targets for Edwards Lifesciences (NYSE: EW). On February 4, 2026, UBS Group AG maintained a “neutral” rating on the stock, setting a price target of $94.00. Earlier, on January 21, 2026, Weiss Ratings reaffirmed their “hold (c)” rating for the company.
These updates reflect ongoing evaluations of Edwards Lifesciences’ market position and financial outlook by various analysts.
**Why this matters**
Analyst ratings and price targets can influence investor sentiment and trading activity. Monitoring these updates helps investors gauge market expectations and make informed decisions regarding Edwards Lifesciences stock.
Source: NewsData